Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
$1.07
$0.90
$0.28
$2.18
$386.80M1.133.43 million shs1.14 million shs
NewLink Genetics Corp stock logo
NLNK
NewLink Genetics
$9.07
$0.82
$3.60
$162.00M1.17547,540 shsN/A
Regulus Therapeutics Inc. stock logo
RGLS
Regulus Therapeutics
$8.16
$8.10
$0.83
$8.35
$564.92M0.351.02 million shsN/A
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
$15.41
-1.9%
$11.57
$5.83
$26.25
$657.22MN/A148,198 shs164,595 shs
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
0.00%-2.73%+16.82%+57.21%-52.44%
NewLink Genetics Corp stock logo
NLNK
NewLink Genetics
0.00%0.00%0.00%0.00%+141.11%
Regulus Therapeutics Inc. stock logo
RGLS
Regulus Therapeutics
0.00%0.00%0.00%+3.95%+353.33%
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
-1.91%-1.60%+50.78%+29.28%+1,540,999,900.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
2.3945 of 5 stars
3.23.00.00.01.52.50.6
NewLink Genetics Corp stock logo
NLNK
NewLink Genetics
N/AN/AN/AN/AN/AN/AN/AN/A
Regulus Therapeutics Inc. stock logo
RGLS
Regulus Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
1.6563 of 5 stars
3.50.00.00.02.30.80.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
2.40
Hold$3.67242.68% Upside
NewLink Genetics Corp stock logo
NLNK
NewLink Genetics
0.00
N/AN/AN/A
Regulus Therapeutics Inc. stock logo
RGLS
Regulus Therapeutics
2.29
Hold$8.504.17% Upside
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
3.00
Buy$36.67137.94% Upside

Current Analyst Ratings Breakdown

Latest NLNK, ZBIO, RGLS, and LXRX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/24/2025
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$4.00
5/16/2025
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$30.00 ➝ $30.00
5/15/2025
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$35.00
(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
$31.21M12.39N/AN/A$0.40 per share2.68
NewLink Genetics Corp stock logo
NLNK
NewLink Genetics
$940K0.00N/AN/A$2.11 per share0.00
Regulus Therapeutics Inc. stock logo
RGLS
Regulus Therapeutics
N/AN/AN/AN/A$1.17 per shareN/A
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
$5M128.92N/AN/A$7.48 per share2.06
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
-$200.40M-$0.51N/AN/AN/A-568.04%-103.16%-54.95%8/6/2025 (Estimated)
NewLink Genetics Corp stock logo
NLNK
NewLink Genetics
-$42.99M-$1.03N/AN/AN/A-4,592.84%-41.50%-33.95%N/A
Regulus Therapeutics Inc. stock logo
RGLS
Regulus Therapeutics
-$46.36M-$0.73N/AN/AN/AN/A-57.53%-53.26%8/6/2025 (Estimated)
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
-$156.99M-$3.55N/AN/AN/AN/AN/A8/21/2025 (Estimated)

Latest NLNK, ZBIO, RGLS, and LXRX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/21/2025Q2 2025
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
-$1.02N/AN/AN/AN/AN/A
8/14/2025Q2 2025
Regulus Therapeutics Inc. stock logo
RGLS
Regulus Therapeutics
-$0.23N/AN/AN/AN/AN/A
8/6/2025Q2 2025
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
-$0.07N/AN/AN/A$4.87 millionN/A
5/15/2025Q1 2025
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
-$1.15-$0.80+$0.35-$0.80$5.00 million$10.00 million
5/13/2025Q1 2025
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
-$0.10-$0.07+$0.03-$0.07$1.26 million$1.26 million
5/8/2025Q1 2025
Regulus Therapeutics Inc. stock logo
RGLS
Regulus Therapeutics
-$0.29-$0.15+$0.14-$0.15N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
N/AN/AN/AN/AN/A
NewLink Genetics Corp stock logo
NLNK
NewLink Genetics
N/AN/AN/AN/AN/A
Regulus Therapeutics Inc. stock logo
RGLS
Regulus Therapeutics
N/AN/AN/AN/AN/A
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
0.48
2.22
2.22
NewLink Genetics Corp stock logo
NLNK
NewLink Genetics
N/A
7.98
7.98
Regulus Therapeutics Inc. stock logo
RGLS
Regulus Therapeutics
N/A
16.31
16.31
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
N/A
6.47
6.47

Institutional Ownership

CompanyInstitutional Ownership
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
74.70%
NewLink Genetics Corp stock logo
NLNK
NewLink Genetics
32.32%
Regulus Therapeutics Inc. stock logo
RGLS
Regulus Therapeutics
92.38%
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
N/A

Insider Ownership

CompanyInsider Ownership
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
13.90%
NewLink Genetics Corp stock logo
NLNK
NewLink Genetics
12.70%
Regulus Therapeutics Inc. stock logo
RGLS
Regulus Therapeutics
4.35%
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
16.50%
CompanyEmployeesShares OutstandingFree FloatOptionable
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
140361.49 million311.25 millionOptionable
NewLink Genetics Corp stock logo
NLNK
NewLink Genetics
5537.33 millionN/ANot Optionable
Regulus Therapeutics Inc. stock logo
RGLS
Regulus Therapeutics
3069.23 million66.22 millionOptionable
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
N/A41.83 million34.93 millionN/A

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Lexicon Pharmaceuticals stock logo

Lexicon Pharmaceuticals NASDAQ:LXRX

$1.07 0.00 (0.00%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$1.08 +0.01 (+0.93%)
As of 08/1/2025 07:45 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.

NewLink Genetics stock logo

NewLink Genetics NASDAQ:NLNK

NewLink Genetics Corporation, a late clinical-stage immuno-oncology company, focuses on discovering and developing novel immunotherapeutic products for the treatment of patients with cancer. It is developing Indoximod, an indoleamine-2, 3-dioxygenase (IDO) pathway inhibitor that is in clinical development in combination with other cancer therapeutics for patients with diffuse intrinsic pontine glioma, pediatric brain tumors, acute myeloid leukemia, and melanoma. The company also develops NLG207 in combination with paclitaxel in recurrent ovarian, fallopian tube, or primary peritoneal cancer; NLG802, a prodrug of indoximod, which has completed Phase I clinical trial; and NLG919, a direct enzymatic inhibitor. The company has collaboration and license agreement with Genentech Inc. for the development and commercialization of NLG919, as well as a research collaboration for the discovery of next generation IDO/TDO inhibitors; and Merck Sharpe & Dohme Corp. to research, develop, and commercialize rVSV G-ZEBOV GP, an Ebola vaccine product candidate. NewLink Genetics Corporation was founded in 1999 and is headquartered in Ames, Iowa.

Regulus Therapeutics stock logo

Regulus Therapeutics NASDAQ:RGLS

Regulus Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.

Zenas BioPharma stock logo

Zenas BioPharma NASDAQ:ZBIO

$15.41 -0.30 (-1.91%)
As of 08/1/2025 04:00 PM Eastern

Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company, which engages in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA.